Meanwhile, silencing experiments targeting ADAR1 were performed on NSCLC cell line 95D, which led to a marked decrease in CYP1A1 editing levels; conversely, knockdown of ADAR2 did not exhibit any significant change in CYP1A1 editing levels compared with the negative control cells (Fig. 2I–K). This evidence concerns the gene ADAR and non-small cell lung carcinoma.